Article Details
Retrieved on: 2025-03-10 20:23:08
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Novo Nordisk’s CagriSema, combining GLP-1 agonist semaglutide and cagrilintide, demonstrating significant weight loss in trials. Biotechnology here focuses on peptide therapeutics for obesity, involving GLP-1 receptor agonists.
Article found on: european-biotechnology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here